1. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

LoVo cells

" in MedChemExpress (MCE) Product Catalog:

39

Inhibitors & Agonists

1

Peptides

7

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14571
    E7820
    5 Publications Verification

    ER68203-00

    Molecular Glues Integrin Infection Metabolic Disease Cancer
    E7820 (ER68203-00), an orally active aromatic sulfonamide derivative, is a molecular glue that induces the targeted degradation of splicing factor RBM39 by recruiting the E3 ubiquitin ligase CUL4-RBX1-DDB1-DCAF15 (CRL4 DCAF15). E7820 is an angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. E7820 inhibits rat aorta angiogenesis with an IC50 of 0.11 μg/ml. E7820 modulates α-1, α-2, α-3, and α-5 integrin mRNA expression. E7820 can be used for the study of acute myeloid leukemia (AML) .
    E7820
  • HY-N9330

    Xanthine Oxidase Cancer
    Broussoflavonol F is a HER2-RAS-MEK-ERK signaling pathway modulator and mushroom tyrosinase inhibitor, with an IC50 of 82.3 μM against mushroom tyrosinase. Broussoflavonol F reduces the protein expression levels of RAS, HER2, phosphorylated BRAF, phosphorylated MEK and phosphorylated Erk. It induces cell apoptosis, triggers G0/G1 phase cell cycle arrest, and exhibits cytotoxicity against colon cancer cells. Broussoflavonol F is applicable to related research on colon cancer .
    Broussoflavonol F
  • HY-50914

    CDK Cancer
    AZD5597 is an inhibitor of CDK with IC50 values of both 2 nM for CDK1 and CDK2. AZD5597 can inhibit the proliferation of tumor cells and has anti-tumor activity .
    AZD5597
  • HY-163697

    Wee1 Apoptosis Cancer
    WEE1-IN-7 (compound 12h) is a potent and orally activeWEE1 inhibitor with an IC50 value of 2.1 nM. WEE1-IN-7 induces apoptosis and cell cycle arrest at the S phase. WEE1-IN-7 shows antitumor activity .
    WEE1-IN-7
  • HY-114340

    Histone Methyltransferase Apoptosis Cancer
    LEM-14 is a potent and selective NSD2 inhibitor with an IC50 of 132 µM. LEM-14 has very weak activitv against NSD1 and has no activity against NSD3. LEM-14 inhibits fibrotic gene expression in ND but not DIO BMDMs. LEM-14 combined with ionizing radiation (IR) enhances the apoptosis rate and reduces the colony-formation ability of CRC cells. LEM-14 exhibits enhanced anti-tumor efficacy in Balb/c nude mice bearing LoVo cell xenografts when combined with ionizing radiation. LEM-14 has the potential for the research of multiple myeloma and colorectal cancer .
    LEM-14
  • HY-161880

    Wee1 Cancer
    WEE1-IN-10 (compound 77) is a Wee1 kinase inhibitor. WEE1-IN-10 shows inhibitory activity on LOVO cell growth, with an IC50 of 0.524 μM. WEE1-IN-10 can be used for the research of diseases caused by abnormal activity of Wee1 .
    WEE1-IN-10
  • HY-177742

    Molecular Glues Phosphoglycerate Dehydrogenase (PHGDH) Cancer
    LXH-3-71 is a PHGDH degrader. LXH-3-71 acts as a molecular glue to enhance the interaction of the PHGDH-DDB1-CRL E3 ligase complex, triggering ubiquitination and proteasomal degradation of PHGDH. LXH-3-71 regulates the stemness of colorectal cancer cells and inhibits tumor proliferation and colony formation. LXH-3-71 can be used in the research of colorectal cancer .
    LXH-3-71
  • HY-171745

    ATM/ATR Cancer
    ATR-IN-32 is an orally active ATR inhibitor. ATR-IN-32 potently inhibits the proliferation of MIA PaCa-2 cells. ATR-IN-32 exerts significant tumor growth inhibition in mice bearing LOVO and HT-29 xenografts. ATR-IN-32 can be used for the study of cancers mediated by ATR protein kinase, such as colorectal cancer, pancreatic cancer .
    ATR-IN-32
  • HY-147569

    ATM/ATR Cancer
    ATR-IN-17 (compound 88) is a potent ATR kinase inhibitor. ATR-IN-17 shows good anticancer activity in LoVo cells, with an IC50 of 1 nM .
    ATR-IN-17
  • HY-147568

    ATM/ATR Cancer
    ATR-IN-16 (compound 46) is a potent ATR kinase inhibitor. ATR-IN-16 shows good anticancer activity in LoVo cells, with an IC50 of 410 nM .
    ATR-IN-16
  • HY-121458

    Apoptosis Cancer
    Nemorosone is the main component of the floral resin of Clusia rosea. Nemorosone has an antiproliferative effect on cancer cells. Nemorosone induces apoptosis in HT-29 and LoVo cells .
    Nemorosone
  • HY-147566

    ATM/ATR Cancer
    ATR-IN-14 (compound 1) is a potent ATR kinase inhibitor. ATR-IN-14 inhibits ATR signaling pathways downstream CHKI protein phosphorylation, with inhibition of 98.03% at 25 nM. ATR-IN-14 shows good anticancer activity in LoVo cells, with an IC50 of 64 nM .
    ATR-IN-14
  • HY-147567

    ATM/ATR DNA-PK PI3K Cancer
    ATR-IN-15 (compound 1) is an orally active and potent ATR kinase inhibitor, with an IC50 of 8 nM. ATR-IN-15 also inhibits human colon tumor cells LoVo, DNA-PK and PI3K, with IC50 values of 47, 663 and 5131 nM, respectively .
    ATR-IN-15
  • HY-149952

    ATM/ATR Cancer
    ATR-IN-23 (Compound 34) is a potent and selective ATR inhibitor with an IC50 of 1.5 nM. ATR-IN-23 has potent antiproliferative effects on LoVo cells and synthetic lethality on HT-29 cells, and can be used in the study of DNA damage response (DDR)-deficient cancers .
    ATR-IN-23
  • HY-175204

    AUTACs SHP2 Apoptosis Autophagy Atg8/LC3 Cancer
    SHP2 protein degrader-3 is a SHP2 AUTAC degrader. SHP2 protein degrader-3 shows dose-dependent SHP2 degradation ability (DC50 = 3.22 μM) and anti-tumor activity (IC50 = 5.59 μM) in HeLa cells. SHP2 protein degrader-3 induces degradation through the LC3-mediated autophagy pathway, which can be inhibited by lysosome inhibitors. SHP2 protein degrader-3 induces apoptosis in various cancer cells (HeLa cells, HepG2 cells, LoVo cells, Huh-7 cells) (SHP2 Ligand : (HY-100388); LC3 Ligand: (HY-10542); Linker : (HY-128834)) .
    SHP2 protein degrader-3
  • HY-168722

    PARP PROTACs Cancer
    PROTAC PARP1 degrader-3 (Compound C6) is a PROTAC degrader for PARP1 with a DC50 of 58.14 nM. PROTAC PARP1 degrader-3 exhibits cytotoxicity in cancer cell SW-620 and LOVO with IC50 of 1.63 μM and 2.84 μM. PROTAC PARP1 degrader-3 exhibits a synergistic effect with SN-38 (HY-13704) in BRCA-mutated colon cancer cell with a combination index (CI) of 0.487. (Blue: Ligand for E3 ligase Cereblon (HY-23095); Pink: Ligand for target protein (HY-10619); Black: Linker (HY-16872))
    PROTAC PARP1 degrader-3
  • HY-W1126467

    Ras Cancer
    RAS-IN-5 (Example 2) is a RAS inhibitor. RAS-IN-5 significantly inhibits the interaction between RAF1 and active KRAS mutant protein or HRAS WT protein. RAS-IN-5 significantly inhibits the cell viability of KRAS, NRAS, and EGFR mutant cells. RAS-IN-5 can be used in the research of colorectal cancer, liver cancer, and non-small cell lung cancer .
    RAS-IN-5
  • HY-147570

    ATM/ATR Cancer
    ATR-IN-18 (compound 2) is an orally active and potent ATR kinase inhibitor, with an IC50 of 0.69 nM. ATR-IN-18 shows antiproliferative activity in LoVo cells, with an IC50 of 37.34 nM. ATR-IN-18 has anti-tumor activity .
    ATR-IN-18
  • HY-159820

    Others Cancer
    Veonetinib (example 3) is a potent inhibitor of tyrosine kinase, with the IC50 of 0.1 μM and 0.4 μM in A549 cells and LOVO cells, respectively .
    Veonetinib
  • HY-176189

    CDK Cancer
    CDK1-IN-7 (compound M7) is a potent CDK1 inhibitor. CDK1-IN-7 inhibits the proliferation and migration of HCT116 and Lovo cells. CDK1-IN-7 can be used in the study of colorectal cancer .
    CDK1-IN-7
  • HY-178038

    Microtubule/Tubulin Reactive Oxygen Species (ROS) Cancer
    Tubulin-IN-56 is a tubulin inhibitor. Tubulin-IN-56 exerts cytotoxic effects against colon cancer cell lines (LS180, HCT116, SW620, LoVo). Tubulin-IN-56 downregulates βIII-tubulin and upregulates βIVa-tubulin in colon cancer cell lines. Tubulin-IN-56 inhibits cell invasiveness and elevates intracellular ROS levels in colon cancer cell lines. Tubulin-IN-56 can be used for the study of colon cancer .
    Tubulin-IN-56
  • HY-168583

    DNA/RNA Synthesis Cancer
    WRN inhibitor 11 (Example 17) is an orally active inhibitor of WRN helicase, with the IC50 of 63 nM .
    WRN inhibitor 11
  • HY-N1268

    Others Others
    Scutebata E is a new neoclerodane diterpenoid isolated from Scutellaria barbata with weak cytotoxic activity .
    Scutebata E
  • HY-N1267

    Others Others
    Scutebata C is a neoclerodane diterpenoid isolated from Scutellaria barbata with weak cytotoxic activity .
    Scutebata C
  • HY-144791

    Bcl-2 Family MDM-2/p53 Caspase Apoptosis Cancer
    Bcl-2-IN-6 (compound 10) is a potent Bcl-2 (B-cell lymphoma-2) inhibitor. Bcl-2-IN-7 down-regulates the expression of Bcl-2, and increases the expression of p53, Bax, and caspase-7 mRNA. Bcl-2-IN-7 induces cell cycle arrest and apoptosis in breast cancer MCF-7 cells. Bcl-2-IN-7 shows good anticancer activity, with IC50 values of 20.91, 22.30, 42.29, and 48.00 μM against MCF-7, LoVo, HepG2, and A549 cell lines, respectively .
    Bcl-2-IN-6
  • HY-144792

    Bcl-2 Family MDM-2/p53 Caspase Apoptosis Cancer
    Bcl-2-IN-7 (compound 6) is a potent Bcl-2 (B-cell lymphoma-2) inhibitor. Bcl-2-IN-7 down-regulates the expression of Bcl-2, and increases the expression of p53, Bax, and caspase-7 mRNA. Bcl-2-IN-7 induces cell cycle arrest and apoptosis in breast cancer MCF-7 cells. Bcl-2-IN-7 shows good anticancer activity, with IC50 values of 20.17, 22.64, 45.57, and 51.50 μM against MCF-7, LoVo, HepG2, and A549 cell lines, respectively .
    Bcl-2-IN-7
  • HY-P10914

    MDM-2/p53 Autophagy Inflammation/Immunology Cancer
    D-CopA3 is the inhibitor for MDM2 and the activator for p53 signaling pathway. D-CopA3 exhibits cytotoxicity in colorectal cancer cells HCT-116, LoVo, and RKO (IC50=15-18 μM), induces JNK/Beclin-1 mediated autophagy. D-CopA3 downregulates the expression of cell cycle inhibitory protein p21Cip1/Waf1, enhances the mucosal barrier function and reduces penetration of inflammatory mediators. D-CopA3 exhibits anti-inflammtory activity in mouse C. difficile toxin A-induced acute enteritis models and DSS (HY-116282)-induced chronic colitis models. D-CopA3 exhibits antitumor efficacy in mouse HCT-116 xenograft models .
    D-CopA3
  • HY-182016

    PROTACs ATM/ATR Checkpoint Kinase (Chk) Apoptosis DNA/RNA Synthesis Caspase Bcl-2 Family MDM-2/p53 Cancer
    PROTAC ATR degrader-3 is a potent CRBN-based ATR PROTAC degrader with a DC50 of 127 nM. PROTAC ATR degrader-3 also degrades CHK1 with an DC50 of 135 nM. PROTAC ATR degrader-3 inhibits cancer cells proliferation, migration and invasion, triggers apoptosis and induces S phase arrest and DNA damage. PROTAC ATR degrader-3 achieves tumor growth inhibition in LoVo xenograft mouse model without apparent toxicity. PROTAC ATR degrader-3 can be used for the research of colorectal cancer .
    PROTAC ATR degrader-3
  • HY-N13192

    Others Cancer
    3-Acetoxyflavone shows antiproliferative activities against LoVo, LoVo/DX and MES-SA cell lines (IC50 from 4.7 μM to 7.8 μM, respectively), which is promising for research of cancers .
    3-Acetoxyflavone
  • HY-149066

    Bacterial Cancer
    Diaporthein B is one of the most highly oxidized pimarane diterpenes. Diaporthein B exhibits activity against M. tuberculosis, with a MIC of 3.1 μg/mL. Diaporthein B reveals IC50s of 1.5-3 μM against HCT 116 and LoVo colon cancer cells .
    Diaporthein B
  • HY-182018

    Target Protein Ligand-Linker Conjugates ATM/ATR Others
    ATR ligand 2-CO-Ph-COOH (Compound 39) is a Target Protein Ligand-Linker Conjugate that incorporates a ligand for ATR (HY-182017) and a PROTAC linker, which recruits E3 ligases. can be used for synthesis of PROTAC ATR degrader-3 (HY-182016) .
    ATR ligand 2-CO-Ph-COOH
  • HY-N16695

    Others Others
    (2S,3S)-Pterosin S 14-O-glucoside is a sesquiterpene glycoside compound that can be isolated from the fern Pteris multifida. (2S,3S)-Pterosin S 14-O-glucoside showed no significant cytotoxicity against A549 (human lung adenocarcinoma), LOVO (colon adenocarcinoma), PANC-1 (human pancreatic cancer), and NCI-H446 (human small cell lung cancer) cell lines (IC50 > 100 μM) .
    (2S,3S)-Pterosin S 14-O-glucoside
  • HY-181678

    DNA-PK HDAC Apoptosis Mitochondrial Metabolism DNA/RNA Synthesis Cancer
    DNA-PK/HDAC6-IN-1 is a selcetive and orally active dual DNA-PK and HDAC6 inhibitor with IC50 values of 84.2 and 64.8 nM. DNA-PK/HDAC6-IN-1 suppresses cancer cells proliferation, induces cancer cell cycle G2/M arrest, apoptosis, and decreases the mitochondrial membrane potential. DNA-PK/HDAC6-IN-1 induces DNA damage and elevates γ-H2AX levels. DNA-PK/HDAC6-IN-1 exhibits antitumor efficacy in AML animal mouse model. DNA-PK/HDAC6-IN-1 can be used for the research of acute myeloid leukemia .
    DNA-PK/HDAC6-IN-1
  • HY-182243

    Hexokinase VDAC Apoptosis AMPK Bcl-2 Family Cancer
    HK2-IN-4 is a selective hexokinase 2 (HK2) inhibitor with an IC50 value of 0.79 μM and a Kd value of 0.41 μM. HK2-IN-4 blocks the interaction between HK2 and voltage-dependent anion channel 1 (VDAC1). HK2-IN-4 reduces lactate and ATP levels in cancer cells. HK2-IN-4 induces the production of apoptosis (apoptosis) markers in cancer cells, including increased p-AMPK/AMPK ratio and Bax levels, as well as decreased Bcl2 levels. HK2-IN-4 inhibits the proliferation of cancer cells with high HK2 expression. HK2-IN-4 can be used in research related to colorectal cancer and non-small cell lung cancer .
    HK2-IN-4
  • HY-183338

    Apoptosis SphK Cancer
    SphK2-IN-4 is a selective SphK2 inhibitor (IC50=6.2 μM) with extremely low activity against SphK1 (IC50 > 50 μM). SphK2-IN-4 exhibits broad-spectrum antiproliferative activity against colorectal cancer cells and induces apoptosis .
    SphK2-IN-4
  • HY-N13817

    NF-κB Inflammation/Immunology Cancer
    (8R,12R,13R)-8,12-Epoxylabd-14-en-13-ol is a diterpene found in Abies georgei. (8R,12R,13R)-8,12-Epoxylabd-14-en-13-ol is a nuclear factor kappa B (NF-κB) inhibitor that inhibits TNFα-triggered NF-κB activity (IC50 = 8.7 μg/mL). (8R,12R,13R)-8,12-Epoxylabd-14-en-13-ol exhibits anti-inflammatory activity and can inhibit NO production. (8R,12R,13R)-8,12-Epoxylabd-14-en-13-ol shows significant cytotoxicity against tumor cells .
    (8R,12R,13R)-8,12-Epoxylabd-14-en-13-ol
  • HY-181863

    NAMPT DNA/RNA Synthesis Apoptosis Cancer
    Nampt-IN-18 (Compound Q24) is an orally active NAMPT inhibitor with an IC50 of 8.0 nM against hNAMPT. Nampt-IN-18 inhibits NAMPT enzymatic activity. Nampt-IN-18 inhibits DNA synthesis and induces Apoptosis. Nampt-IN-18 exhibits anticancer activity against gastric cancer and colorectal cancer. Nampt-IN-18 can be used for the research of gastrointestinal cancers .
    Nampt-IN-18
  • HY-182017

    Ligands for Target Protein for PROTAC ATM/ATR Others
    ATR ligand 2 (Compound 26) is a ATR PROTAC ligand. ATR ligand 2 can be conjugated with E3 ligase Ligand (HY-W077589A) and linker to synthesize PROTAC ATR degrader-3 (HY-182016) .
    ATR ligand 2
  • HY-181848

    DNA-PK Apoptosis Cancer
    DNA-PK-IN-16 is an orally active DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 of 10.2 nM. DNA-PK-IN-16 induces the upregulation of γH2A.X, a biomarker of DNA double-strand breaks. DNA-PK-IN-16 exhibits antiproliferative activity in various cancer cell lines. DNA-PK-IN-16 enhances the infiltration of CD8 + T cells in tumor tissues through synergistic action with anti-PD-L1 monoclonal antibody. DNA-PK-IN-16 is applicable for cancer research .
    DNA-PK-IN-16

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: